Search Results for: Pharma: Other News to Note
-
Other News To Note
T3D expects to reposition DB959 as a central nervous system therapy, using its neuroprotective potential to address multiple Alzheimer's disease pathologies, including neuroinflammation, neuronal cell loss, neurotransmitter deficits, tau neurofibrillary tangles and insulin resistance/lowered cerebral glucose metabolism...commercial rights to Bionect (hyaluronic acid sodium salt, 0.2 percent) in oncology markets from Innocutis Holdings LLC to concentrate on niche products for oncology and oncologyBioWorld Today | Wednesday, June 19, 2013 -
Pharma: Other News To Note
The new facility will primarily handle the blister packaging of Eisai's investigational treatment lenvatinib which is used to treat thyroid cancer as well as other types of solid tumors...Teva will now have access to Microdose's technology including its multidose dry powder nebulizer device...Stifel acted as exclusive financial advisor to Microdose in the transactionBioWorld Today | Tuesday, June 18, 2013 -
Pharma: Other News To Note
The companies have agreed to collaborate in China on the development and commercialization of the subcutaneous formulation of BMS' Orencia (abatacept), for the treatment of rheumatoid arthritis...Costs related to the reorganization are not expected to have a material effect on the group's financesBioWorld Today | Monday, June 17, 2013 -
Pharma: Other News To Note
Astrazeneca will have first rights to the molecules discovered through the agreement and can choose further development in exchange for royalty payments to Cancer Research Technology...The big pharma will have first rights of negotiation on any promising drug targets that result from the testing agreementBioWorld Today | Friday, June 14, 2013 -
Other News To Note
Xgeva previously gained approval in 2010 to prevent fractures when cancer has spread to the bone. (See BioWorld Today, Nov. 22, 2010...Madera has identified small-molecule compounds designed to increase the expression of apolipoprotein E (apoE), which has been shown to mediate beta-amyloid clearance from the brain and prevent its accumulation into the plaques that are characteristic of Alzheimer'sBioWorld Today | Friday, June 14, 2013 -
Other News To Note
Aphios Corp., of Woburn, Mass., said it entered joint research collaboration and commercialization agreements with Vivacell Biotechnology Espana SL, of Cordoba, Spain, to develop therapeutics for multiple sclerosis and other neurodegenerative diseases of the central nervous system...That is in contrast to some other antibiotics, such as linezolid (Zyvox), which causes drug interactions when taken with selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors...ZealandBioWorld Today | Thursday, June 13, 2013 -
Other News To Note
Bioalliance Pharma SA, of Paris, started a Phase II trial evaluating the efficacy and safety of Validive (clonidine Lauriad) in the U.S...In other news, Biolinerx said it signed an out-licensing agreement with Jiagsu chia-tai Tianqing Pharmaceutical CoBioWorld International | Wednesday, June 12, 2013 -
Pharma: Other News To Note
Breckenridge Pharmaceutical Inc., of Boca Raton, Fla., entered into a development agreement with Welding GmbH & Co., of Hamburg, Germany, and SK Chemicals, of Seoul, South Korea, to develop and market an undisclosed drug candidate with potential U.S.-branded sales of approximately $500 million...Fluzone Quadrivalent vaccine includes two A strains and two B strains to help protect against influenza diseaseBioWorld Today | Tuesday, June 11, 2013 -
Pharma: Other News To Note
Safyral is approved to prevent pregnancy in women who elect to use an oral contraceptive and to provide a daily dose of folate supplementationBioWorld Today | Friday, June 7, 2013 -
Other News To Note
Royalty Pharma, of New York, extended until June 21 the $6.4 billion offer to buy Elan Corp...The company expects to enter a third agreement (separation agreement) governing other terms of the firms' business relationshipBioWorld Today | Friday, June 7, 2013 -
Pharma: Other News To Note
Astellas Pharma US Inc., of Northbrook, Ill., part of Astellas Pharma Inc., entered a distribution agreement with Tecnofarma International Ltd., of Buenos Ares, Argentina, to distribute enzalutamide (Xtandi in the U.S.) in Latin America, excluding Brazil, upon regulatory approvals in the various countriesBioWorld Today | Thursday, June 6, 2013 -
Pharma: Other News To Note
Under priority review, the FDA aims to complete its review within an eight-month review cycleBioWorld Today | Wednesday, June 5, 2013 -
Other News To Note
Horizon Pharma Inc., of Deerfield, Ill., said in an SEC filing that it provided written notice to Mallinckrodt LLC, the pharmaceuticals business of Dublin, Ireland-based Covidien LLC, of the termination of the companies' co-promotion agreement dated June 14, 2012, effective 30 days after the date of such notice...to purchase all of the outstanding capital stock of ProFibrix, subject to the former's satisfactory review of the pending Phase III trial results with Fibrocaps, a dry powder topicalBioWorld Today | Wednesday, June 5, 2013 -
Pharma: Other News To Note
to manufacture, market and sell six dermatology and three antiviral products from GSK...patients to continue to have access to treatments and allows the Stiefel U.SBioWorld Today | Tuesday, June 4, 2013 -
Other News To Note
AstraZeneca is planning to develop ISIS-ARRx broadly to treat patients under a variety of settings during the course of prostate cancer treatment, including both as a single agent and in combination therapy...Maxygen Inc., of Redwood City, Calif., said its board approved the liquidation and dissolution of the company, subject to shareholder approval, and plans to distribute all available cash to its shareholders after making reasonable provision for known and potential liabilities and otherBioWorld Today | Tuesday, June 4, 2013 -
Pharma: Other News To Note
Shire plc, of Dublin, settled litigation against Teva Pharmaceuticals USA Inc., a division of Teva Pharmaceutical Industries Ltd., of Jerusalem, related to Teva's abbreviated new drug application for a generic version of Shire's Intuniv (guanfacince) for attention deficit hyperactivity disorder...The settlement allows Teva a license to market its own generic versions of Intuniv or authorized versions of Intuniv provided by ShireBioWorld Today | Monday, June 3, 2013 -
Pharma: Other News To Note
As of the end of April, 943 employees, or about 77 percent, have had their future employment status clarified, including 300 employees who accepted the offer of transfers to other Merck Serono sites, 43 people who were redeployed through the creation of seven start-up companies and 80 employees that accepted early retirement...Merck Serono decided last year to shutter its Geneva headquarters. (See BioWorld Today, June 20, 2012BioWorld Today | Friday, May 31, 2013 -
Pharma: Other News To Note
In other news, Perrigo received approval for the generic version of Sanctura XR (trospium chloride; Allergan Inc.) to treat overactive bladder with symptoms of urge urinary incontinence, urgency and urinary frequencyBioWorld Today | Thursday, May 30, 2013 -
Other News To Note
IBC Generium is granted an exclusive license for other territories, and also has the right to an exclusive license for Russia and CIS states...Cardiome Pharma Corp., of Vancouver, British Columbia, said its board adopted an advance notice policy regarding the nomination of directors, establishing a deadline and written process by which registered or beneficial holders of the company's common shares (NASDAQ:CRME) must submit nominations to the company prior to an annual or special shareholderBioWorld Today | Thursday, May 30, 2013 -
Pharma: Other News To Note
In separate news, Valeant said it received a received a complete response letter from the FDA for its new drug application for efinaconazole to treat onychomycosis...Questions raised by the FDA pertain to chemistry, manufacturing and controls related to areas of the container closure apparatusBioWorld Today | Wednesday, May 29, 2013
Category
Current Filters
- xNOT European Medicines
Related Keywords
Categories
- x BioWorld Today (1881)
- x BioWorld International (361)
- x BioWorld Insight (44)
- x Bio Perspectives (26)
- x State of the Industry Report (5)
- x BioWorld Snapshots (1)
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.